|
1) Fukuchi Y, Nishimura M, Ichinose M, et al. Prevalence of chronic obstructive pulmonary disease in Japan: results from Nippon COPD epidemiology (NICE) study. Eur Respir J. 2001; 18: 275
|
|
|
|
|
2) Teramoto S, Yamamoto H, Yamaguchi Y, et al. Global burden of COPD in Japan and Asia. Lancet. 2001; 362: 1764-5
|
|
|
|
|
|
3) Fabbri LM, Luppi F, Beghe B, et al. Complex chronic comorbidities of COPD. Eur Respir J. 2008; 31: 204-12
|
|
|
|
|
4) Gan WQ, Man SFP, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004; 59: 574-80
|
|
|
|
|
|
5) de Torres JP, Cordoba-Lanus E, Lopez-Aquilar C, et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J. 2006; 27: 902-7
|
|
|
|
|
|
6) Dahl M, Vestbo J, Lange P, et al. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007; 175: 250-5
|
|
|
|
|
|
7) Groenewegen KH, Postma DS, Hop WC, et al. COSMIC Study Group, Increased systemic inflammation is a risk factor for COPD exacerbations. Chest. 2008; 133: 350-7
|
|
|
|
|
|
8) Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome？ Lancet. 2007; 370: 797-9
|
|
|
|
|
|
9) Valipour A, Schreder M, Wolzt M, et al. Circulating vascular endothelial growth factor and systemic inflammatory markers in patients with stable and exacerbated chronic obstructive pulmonary disease. Clin Sci(Lond). 2008; 115: 225-32
|
|
|
|
|
|
10) Sabit R, Bolton CE, Edwards PH, et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007; 175: 1259-65
|
|
|
|
|
|
11) Iwamoto H, Yokoyama A, et al. Airflow limitation in smokers is associated with subclinical atherosclerosis. Am J Respir Crit Care Med. 2009; 179: 35-40
|
|
|
|
|
|
12) Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007; 356: 775-89
|
|
|
|
|
|
13) Donald P, Bartolome Celli, Stephen Senn, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008; 359: 1543-54
|
|
|
|
|
|
14) Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008; 300: 1439-50
|
|
|
|
|
|
15) Hawkins NM, Huang Z, Karen S, et al. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur J Heart Fail. 2009; 11: 292-8
|
|
|
|
|
|
16) Janda S, Park K, FitzGerald JM, et al. Statins in COPD. Chest. 2009; 136: 734. http://www.chestjournal.org/content/early/2009/04/17/chest.09-0194
|
|
|
|
|
|
17) Blamoun AI, Batty GN, Debari VA, et al. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int J Cin Pract. 2008; 62: 1373-8
|
|
|
|
|
|
18) Frost FJ, Petersen H, Tollestrup K, et al. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest. 2007; 131: 1006-12
|
|
|
|
|
|
19) Ishida W, Kajiwara T, Ishii M, et al. Decrease in mortality rate of chronic obstructive pulmonary disease (COPD) with statin use: a population-based analysis in Japan. Tohoku J Exp Med. 2007; 212: 265-73
|
|
|
|
|
20) Keddissi JI, Younis WG, Chbeir EA, et al. The use of statins and lung function in current and former smokers. Chest. 2007; 132: 1764-71
|
|
|
|
|
|
21) Lee TM, Lin MS, Chang NC. Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am J Cardiol. 2008; 101: 530-5
|
|
|
|
|
|
22) Mancini GB, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol. 2006; 47: 2554-60
|
|
|
|
|
|
23) Melbye H, Halvorsen DS, Hartz I, et al. Bronchial airflow limitat ion, smoking, body mass index, and stain use are strongly associated with the C-reactive protein level in the elderly. The Tromso Study 2001. Respir Med. 2007; 101: 2541-9
|
|
|
|
|
|
24) Soyseth V, Brekke PH, Smith P, et al. Statins use is associated with reduced mortality in COPD. Eur Respir J. 2007; 29: 279-83
|
|
|
|
|
|
25) Van Gestel YR, Hoeks SE, Sin DD, et al. Effect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease. Am J Cardial. 2008; 102: 742-7
|
|
|
|
|
|
26) Mortensen EM, Copeland LA, Pugh MJ, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res. 2009; 10: 45
|
|
|
|
|